Skip to content

Debt Issuance Costs at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$1.98M
HRO
HarrowHROW
$113K
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$4.95M

Other financials

Income statement

See full
Revenue$171.2M+0.4%
Gross profit$70.3M-17.5%
Operating income$13.6M-63.5%
Net income$6.4M-74.6%
EPS (diluted)$0.14-72.5%

Balance sheet

See full
Cash & equivalents$170.9M-6.5%
Total debt$686.6M+5.2%
Total equity$445.5M
Total assets$1.6B+1.3%

Cash flow

See full
Operating cash flow$47.8M+36.4%
CapEx$9.5M-11.1%
Free cash flow$38.3M+57.2%

Valuation

See full
Market cap$927.72M-19.9%
Enterprise value$1.44B-11.3%
P/E11.7×+3.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin47.3%-3.2pp
Operating margin16.2%-10.4pp
Net margin11%-8.4pp
FCF margin18.8%-1.8pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio3.9×+0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Amphastar Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amphastar Pharmaceuticals's debt issuance costs?
Amphastar Pharmaceuticals (AMPH) reported debt issuance costs of $8K in Q4 2025.
What does debt issuance costs mean?
Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.